0.1742
-0.0036
(-2.02%)
At close: January 31 at 3:29:01 PM GMT+1
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Carlos de Sousa | Chief Executive Officer | 467.59k | -- | 1958 |
| Mr. Hans Vassgard Eid | Chief Financial Officer | 267.71k | -- | -- |
| Mr. Audun Tornes | Chief Technology Officer | 175.87k | -- | -- |
| Mr. Jens Egil Torbjorn Bjorheim M.D., Ph.D. | Chief Medical Officer | 258.03k | -- | -- |
| Mr. Oivind Foss Ph.D. | Head of Clinical Operations | 152.78k | -- | -- |
| Orla Mc Callion | Head of Regulatory Affairs & QA | 144.55k | -- | -- |
| Torill Trones | Head of Office | -- | -- | -- |
Ultimovacs ASA
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 17
Description
Ultimovacs ASA, a biotech company, develops immunotherapies against cancers in Norway. Its lead product candidate is UV1, a peptide-based therapeutic cancer vaccine that induces a specific T cell response against the pan-tumor antigen telomerase. Ultimovacs ASA was incorporated in 2011 and is headquartered in Oslo, Norway.
Corporate Governance
Ultimovacs ASA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
January 31, 2025 at 6:00 AM UTC
Ultimovacs ASA Earnings Date
Recent Events
Recent Events Information Not Available